Stephanie L. Schonewald, PhD

Dr. Stephanie Schonewald counsels biotech and pharmaceutical companies on the strategic development of patent portfolios, patent prosecution, and post-grant patent challenges.

Stephanie advises clients who are involved in contentious patent scenarios. She has handled a variety of third party submissions, protests, and post-grant proceedings before the United States Patent and Trademark Office (USPTO). She has worked on over 55 inter partes review, post grant review, and covered business method review proceedings before the Patent Trial and Appeal Board (PTAB).

Stephanie also advises clients on the management of their US patent office activity alongside other global patent activity. For example, she routinely consults with clients on European third party observations and oppositions. She has also consulted with clients on post-grant challenges in other key jurisdictions, including Australia and Japan.

Stephanie’s skills in managing patent disputes were developed, in part, through her district court patent litigation experience. She has litigated and advised clients regarding complex patent infringement and validity issues in a variety of jurisdictions across the country.

Stephanie’s clients include Regeneron Pharmaceuticals, Inc., Foundation Medicine, Inc., BioNTech SE, Akouos, Inc., Momenta Pharmaceuticals, Inc., Progenics Pharmaceuticals, and Saudi Arabian Oil Company.


  • A World’s Leading Patent Practitioner by IAM Patent 1000 (2022)
  • A “Top 50 Women in PTAB Trials” by the PTAB Bar Association
  • Best Lawyers in America: “Ones to Watch (2021, 2023)

Representative Engagements

Patent Trial and Appeal Board

  • Triplet Therapeutics, Inc. v. Board of Supervisors of Louisiana State University and Agricultural and Mechanical College, PTAB: Counsel for Patent Owner Louisiana State University and interested party Takeda Pharmaceuticals U.S.A., Inc. in defense of Louisiana State University’s patent directed to oligonucleotide compositions targeting the DNA mismatch repair system for the treatment of associated DNA repeat expansion diseases.
  • Valo Early Discovery, Inc. v. Hybrigenics SA., Fed. Circ.: Counsel for Valo Early Discovery, Inc. (f/k/a Integral Early Discovery, Inc.) in an appeal of a PTAB post-grant review decision involving a patent protecting novel inhibitors of ubiquitin-specific protease 7 (USP7).
  • Guardant Health, Inc. v. Foundation Medicine, Inc., PTAB: Counsel for Foundation Medicine in IPR proceedings defending patents protecting innovative comprehensive genomic cancer assays using next generation sequencing.
  • Foundation Medicine, Inc. v. Guardant Health, Inc., PTAB: Counsel for Foundation Medicine in IPR proceedings challenging patents directed to methods for detecting genetic mutations.
  • Regeneron Pharm., Inc. v. Kymab Ltd., PTAB: Counsel for Regeneron in multiple IPR proceedings challenging patents directed to transgenic mice and methods of using transgenic mice.
  • Daiichi Sankyo Co., Ltd. v. Alethia Biotherapeutics, Inc., PTAB: Counsel for Alethia in defense of its patent directed to antibodies for inhibiting bone resorption.
  • Progenics Pharmaceuticals, Inc. v. Max-Planck-Gesellschaft zur Förderung der Wissenschaften e. V., PTAB: Counsel for Progenics Pharmaceuticals, Inc. in a PGR proceeding challenging a patent directed to compounds for preparing 18F-radiolabeled Prostate-Specific Membrane Antigen (PSMA)-targeting conjugates.
  • Hybrigenics SA v. FORMA Therapeutics, Inc., PTAB: Counsel for FORMA Therapeutics, Inc. in a PGR proceeding defending a patent protecting novel inhibitors of ubiquitin-specific protease 7 (USP7).
  • Saudi Arabian Oil Co. v. SK Innovation Co. Ltd., PTAB: Counsel for Saudi Arabian Oil Co. in an IPR proceeding challenging a patent directed to polycarbonates.
  • ADT LLC, et al. v. Script Security Solutions LLC, PTAB: Counsel for, Inc. in proceedings challenging patents directed to a portable security alarm system.
  •, Inc. v. Rothschild Broadcast Distribution Sys., LLC, PTAB: Counsel for, Inc. in an IPR proceeding challenging a patent directed to systems and methods for media content storage and delivery.
  • Central Security Group - Nationwide, Inc. et al. v. Ubiquitous Connectivity, LP, PTAB: Counsel for Central Security Group in challenging patents related to the use of SMS (short message service) messages and cellular networks to control and monitor environmental devices.
  • Akamai Technologies, Inc. v. Limelight Networks, Inc., PTAB: Counsel for Akamai Technologies, Inc. in challenging a patent related to retrieving content objects in a content delivery network.
  • Oil States Energy Services, LLC v. Greene’s Energy Group, LLC, et al., Supreme Court: Counsel for the Boston Patent Law Association in filing amicus brief in support of neither party on the merits.

Patent Prosecution and Counseling

  • Preparation and global prosecution of patent applications directed to diagnostic and therapeutic products including antibodies, gene therapies, vaccines, stem cells, pharmaceutical formulations, nanotechnology, nucleic acid molecules, biologics, medical devices, mouse platforms for antibody development, and methods of treating diseases.
  • Counseled a large immunology company in defending its patents and challenging its competitors’ patents involved in European Oppositions.
  • Defended two patents through Supplemental Examination.
  • Conducted prior art searches and drafts opinions.

Publications and Presentations

  • “The Secrets to PTAB Success: Advanced IPR Strategies,” moderator, IPWatchDog: PTAB Masters, February 2023.
  • “The Future of the Written Description Requirement,” moderator, IPWatchdog: Life Sciences Masters, October 2022.
  • “Enhancing Your Research & Development Pipeline,” moderator, Consero IP Life Sciences Executive Roundtable, March 2022.
  • Patent Specification Concerns Make IPRs Tricky For Drug Cos.,quoted, Law360, January 2022.
  • “Life Sciences and IPR: Orange Book & Biologic Patents at the PTAB,” panelist, IP Watchdog PTAB Masters 2022, January 2022.
  • “Section 112 Enablement: What to Watch Out For,” panelist, BIO IP Counsels Committee Webinar, September 2021.
  • “Patent Challengers Reassess Strategies After Ruling Bars Tactic,” quoted, Bloomberg Law, June 2020.
  • “Boston’s Top Women at the PTAB,” moderator, Boston Patent Law Association, February 2020.
  • Patent Office Guidance at Odds With Court Strategy, Attorneys Say,” quoted, Bloomberg Law, February 2020.
  • “In the Hot Seat - Case Law Update and Trends,” panelist, BIO IPCC Fall Conference, November 2019.
  • “Mission Incomprehensible – Indefiniteness and Support in Post-Grant Trials,” webinar panelist, American Intellectual Property Law Association (AIPLA), October 2019.
  • “Precluding the Problem: Tips and Pitfalls for Prosecutors,” panelist, American Intellectual Property Law Association (AIPLA) Spring Meeting, May 2019.
  • “Patent Cases Round-Up,” panelist, 2019 American Bar Association-Intellectual Property Law (ABA-IPL) Annual Meeting and 34th Intellectual Property Law Conference, April 2019.
  • “How to Make ‘Connections’ and ‘Friends’ in 140 Characters or Less: Social Networking for Lawyers,” webinar panelist, the Federal Circuit Bar Association, March 2019.
  • “Networking for Young Lawyers,” webinar panelist, the Federal Circuit Bar Association, January 2019.
  • “PTAB Practice Post-SAS: What You Need To Know,” moderator, Boston Bar Association, December 2018.
  • “Post-Grant Amendments at the USPTO,” panelist, Boston Patent Law Association, June 2017.
  • “Practical Tips For Tackling Your First Couple of Years As An Associate,” panelist, Federal Circuit Bar Association, February 13, 2017.
  • “Will The Pendulum Swing Back In IPR Proceedings?”, co-author, IP Law360, April 2015.
  • "AIA Post-Grant Proceedings: Multiple Petitioners Filing a Single Petition Must Present their Case with a ‘Single Voice,’” co-author, February 2014.
  • “AIA Post-Grant Proceedings: Rejection of Invalidity Defenses at District Court did not Prohibit PTAB’s Later Finding of Unpatentability,” co-author, February 2014.
  • “Diverse Career Paths,” panelist , Federal Circuit Bar Association, September 18, 2012.
  • “Mock Appellate Argument,” co-presenter, AUTM-LES Joint Meeting, March 14, 2012.
  • “The Mouse TrkB mRNA Contains Two IRESes that are Differentially Regulated,” co-author, PLoS ONE, September 2008.
  • "Identification of Intrinsic and Extrinsic Determinants that Regultae Internal Initiation of Translation Mediated by the FMRI 5’ Leader," co-author, BMC Mol. Bio., October 2008.

Professional and Community Involvement

  • Boston Patent Law Association (Co-Chair of the Contested Matters Committee)
  • Boston Intellectual Property American Inn of Court
  • PTAB Bar Association (Women’s Committee)
  • American Intellectual Property Law Association
  • American Bar Association
  • Federal Circuit Bar Association

Education & Credentials

University of Denver Sturm College of Law
JD, 2009, Torts and Administrative Law, with honors
University of Colorado at Denver Health Sciences Center
PhD, 2006, Biochemistry and Molecular Genetics
University of Northern Iowa
BS, 2000, summa cum laude




District of Columbia

U.S. District Court, Eastern District of Texas

U.S. Patent & Trademark Office

Stephanie's Insights